Our Take
Standard vendor pitch for manual curation services dressed as AI strategy advice, with no benchmarks or case studies.
Why it matters
Pharma teams are evaluating data strategies for AI repurposing workflows as computational approaches scale but success rates remain low.
Do this week
Data teams: audit your current repurposing datasets for fragmentation and inconsistent annotations before expanding model capacity.
QIAGEN makes case for curated data in AI repurposing
QIAGEN published sponsored content arguing that oncology AI repurposing efforts fail due to fragmented data rather than insufficient scale. The company contends that manually curated knowledge graphs mapping causal relationships between genes, variants, pathways and diseases produce more reliable AI insights than larger, unstructured datasets.
The piece targets teams already applying AI to indication expansion, claiming that "bigger models don't solve all problems when the foundational data are fragmented or inconsistent." QIAGEN positions expert curation as necessary because AI "can't reliably fact-check the data, analyze study design or distinguish correlation from causation."
Scale versus quality debate hits drug repurposing
The argument touches a real tension in computational drug discovery. Teams have access to massive oncology datasets including genomic profiles, pathway data, drug-target interactions and clinical outcomes, but repurposing success rates remain limited. The question is whether better results come from more sophisticated models processing larger datasets or higher-quality foundational data.
QIAGEN's framing reflects broader vendor positioning as companies selling curation services compete against pure-play AI approaches. The company offers no benchmarks comparing curated versus raw data performance, making this primarily a market positioning play rather than technical guidance.
Evaluate curation claims with concrete metrics
Teams evaluating data strategies should demand specific performance comparisons. Ask vendors for head-to-head benchmarks showing curated data advantages in terms of prediction accuracy, false positive rates, or successful repurposing identifications. Most curation pitches rely on intuitive arguments about data quality without quantifying the downstream impact.
Consider hybrid approaches that combine automated processing with targeted expert review for high-confidence predictions. Pure manual curation doesn't scale, but selective human validation of AI-identified candidates can capture benefits of both approaches. Focus curation budgets on the specific data types and relationships most critical for your repurposing targets rather than comprehensive dataset cleanup.